1. Bang HO, Dyerberg J. Plasma lipids and lipoproteins in Greenlandic west coast Eskimos. Acta Med Scand 1972; 192: 85-94.
2. Dyerberg J, Bang HO, Hjorne N. Fatty acid composition of the plasma lipids in Greenland Eskimos. Am J Clin Nutr 1975; 28: 958-66.
3. Das UN. Essential fatty acids: biochemistry, physiology and pathology. Biotechnol J 2006; 1: 420-39.
4. Harris WS, Miller M, Tighe AP, Davidson MH, Schaefer EJ. Omega-3 fatty acids and coronary heart disease risk: clinical and mechanistic pers¬pectives. Atherosclerosis 2007; 197: 12-24.
5. Das NU. Essential fatty acids- A review. Curr Pharm Biotechnol 2006; 7:
467-82.
6. Nakamura MT, Nara TY. Structure, function, and dietary regulation of A6, A5, and A9 desaturases. Annu Rev Nutr 2004; 24: 345-76.
7. Brenner RR. Nutritional and hormonal factors influencing desaturation of essential fatty acids. Prog Lipid Res 1982; 20: 41-8.
8. Tang C, Cho HP, Nakamura MT, Clarke SD. Regulation of human del-ta-6 desaturase gene transcription: identification of a functional direct re-
peat-1 element. J Lipid Res2003; 44: 686-95.
9. Das UN. A defect in the activity of A6 and A5 desaturases may be a factor predisposing to the development of insulin resistance syndrome. Prostaglandins Leukot Essent Fatty Acids 2005; 72: 343-50.
10. Horrobin DF. The regulation of prostaglandin biosynthesis by the mani¬pulation of essential fatty acid metabolism. Rev Pure Appl Pharmacol Sci
1983; 4: 339-83.
11. Meyer BJ, Mann NJ, Lewis JL ve ark. Dietary intakes and food sources of omega-6 and omega-3 polyunsaturated fatty acids. Lipids2003; 38: 391-8.
12. Sanders TAB. Essential and trans-fatty acids in nutrition. Nutr Res Rev 1988; 1: 57-8.
13.
Taşa
n M. Dağlıoğlu O. Trans yağ asitlerinin yapısı, oluşumu ve gıdalarla alınması. Tekirdağ Ziraat Fakültesi Dergisi 2005; 2: 79-88.
14. Mensink RP, Katan MB. Effect of dietary trans fatty acids on high-den¬sity and low-density lipoprotein cholesterol levels in healthy subjects. N Eng J Med 1990; 323: 439-45.
15. Sackh FM, Stone PH, Gibson CM, Silverman DI, Rosner B, Pasternak RC. Controlled trial of fish oil regression of human coronary atheroscle¬rosis. HARP Research Group. J Am Cardiol1995; 25: 1492-8.
16. Yokoyama M, Origasa H, Matsuzaki M ve ark. On behalf of the Japan EPA Lipid Intervention Study (JELIS) Investigators. Effects of eicosa-pentaenoic acid on major coronary events in hypercholesterolaemic pati-
ents: a randomised open-label, blinded endpoint analysis. Lancet 2007;
369: 1090-8.
17. Richter WO, Jacob BG, Ritter MM, Schwandt P. Treatment of primary chylomicronemia due to familial hypertriglyceridemia by omega-3 fatty acids. Metabolism 1992; 41: 1100-5.
18. Dehmer GJ, Popma JJ, van den Berg EK ve ark. Reduction in the rate of early restenosis after coronary angioplasty by a diet supplemented with n-
3 fatty acids. N Engl J Med1988; 319: 733-40.
19. Leaf A. Dietary prevention of coronary heart disease: the Lyon Diet He¬art Study. Circulation 1999; 99: 733-5.
20. De Lorgeril M, Salen P, Martin JL, Monjaud I, Delaye J, Mamelle N. Mediterranean diet, traditional risk factors, and the rate of cardiovascular complications after myocardial infarction: final report of the Lyon Diet
Heart Study. Circulation 1999; 99: 779-85.
21. Marchioli R, Schweiger C, Tavazzi L, Valagussa F. Efficacy of n-3 pol-yunsaturated fatty acids after myocardial infarction: results of GISSI-Pre-venzione trial. Gruppo Italiano per lo Studio della Sopravvivenza nell'In-farto Miocardico. Lipids2001; 36: 119-26.
22. Bucher HC, Hengstler P, Schindler C, Meier G. N-3 polyunsaturated fatty acids in coronary heart disease: a meta-analysis of randomized con¬trolled trials. Am J Med2002; 112: 298-304.
23. Oomen CM, Ocke MC, Feskens EJ, Kok FJ, Kromhout D. Alpha-Lino-
lenic acid intake is not beneficially associated with 10-y risk of coronary artery disease incidence: the Zutphen Elderly Study. Am J Clin Nutr
2001; 74: 457-63.
24. Nilsen DW, Albreksten G, Landmark K, Moen S, Aarsland T, Woie L. Effects of a high-dose concentrate of n-3 fatty acids or corn oil introdu¬ced early after an acute myocardial infarction on serum triacylglycerol and HDL cholesterol. Am J Clin Nutr 2001; 74: 50-6.
25. Schacky C. Omega-3 fatty acids and cardiovascular disease. Curr Opin
Clin Nutr Metab Care 2007; 10: 129-35.
26. De Caterinaa R, Zampolli A. Omega-3 fatty acids, atherogenesis, and en-dothelial activation. Cardiovasc Med 2007; 8: 11-4.
27. Harris WS, von Schacky C. The omega-3 index: a new risk factor for death from coronary heart disease? Prev Med 2004; 39: 212-20.
28. von Schackya C, Haris WS. Cardiovascular risk and the omega -3 index.
J Cardiovasc Med2007; 8: 46-9.
29. Nakamura N, Ohta M, Okuda K ve ark. Joint effects of HMG-CoA re-ductase inhibitors and eicosapentaenoic acids on serum lipid profile and plasma fatty acid concentrations in patients with hyperlipidemia. Int J Clin Lab Res 1999; 29: 22-5.
30. Bezard J, Blond J, Bernard A, Clouet P. The metabolism and availability of essential fatty acids in animal and human tissues. Semin Nephrol 1994;
34: 539-68.
31. Collins T, Read MA, Neish AS, Whitley MZ, Thanos D, Maniatis T.
Transcriptional regulation of endothelial cell adhesion molecules: NF-
kappa B and cytokine-inducible enhancers. FASEB J1995; 9: 899-909.
32. Bonaa KH, Bjerve KS, Nordoy A. Docosahexaenoic and eicosapentaeno-ic acids in plasma phospholipids are divergently associated with high den¬sity lipoprotein in humans. Arterioscler Thromb 1992; 12: 675-81.
33. Riserus U. Fatty acids and insulin sensitivity. Curr Opin Clin Nutr Metab
Care 2008; 11: 100-5.
34. Nakamura N, Hamazaki T, Jokaji H, Minami S, Kobayashi M. Effect of HMG-CoA reductase inhibitors on plasma polyunsaturated fatty acid
>5
LU O H
128
Konukoğlu D | Omega-3 ve omega-6 yağ asitlerinin özellikleri, etkileri ve kardiyovasküler hastalıklar ile ilişkileri
concentration in patients with hyperlipidemia. Int J Clin Lab Res1998; 28:
192-5.
35. Narayanan BA, Narayanan K, Simi B, Reddy BS. Modulation of ınducib-le nitric oxide synthase and related proinflammatory genes by the omega-3 fatty acid docosahexaenoic acid in human colon cancer cells. Cancer Res
2003; 63: 972-9.
36. Kumar KV, Das UN. Effect of cis-unsaturated fatty acids, prostaglandins, and free radicals on angiotensin-converting enzyme activity in vitro. Proc Soc Exp Biol Med 1997; 214: 374-9.
37. Kaergel E, Muller DN, Honeck H, Theuer J ve ark. P450-dependent arachidonic acid metabolism and angiotensin-II-induced renal damage. Hypertension 2002; 40: 273-9.
38. Danao-Camara TC, Shintani TT. The dietary treatment of inflammatory arthritis: case reports and review of the literature. Hawaii Med J 1999; 58:
126-31.
39. Li H, Ruan XZ, Powis SH, Fernando R ve ark. EPA and DHA reduce LPS-induced inflammation responses in HK -2 cells: evidence for a PPAR-gamma-dependent mechanism. Kidney Int 2005; 67: 867-74.
40. Okuda Y, Kawashima K, Sawada T ve ark. Eicosapentaenoic acid enhan¬ces nitric oxide production by cultured human endothelial cells. Biochem BiophysRes Commun 1997; 232: 487-91.
41. Marcheselli VL, Hong S, Lukiw WJ ve ark. Novel docosanoids inhibit brain ischemia-reperfusion-mediated leukocyteinfiltration and pro-inf¬lammatory gene expression. J Biol Chem 2003; 278: 43807-17.
42. Hong S, Gronert K, Devchand PR, Moussignac RL, Serhan CN. Novel docosatrienes and 17S-resolvins generated from docosahexaenoic acid in murine brain, human blood, and glial cells. Autacoids in anti-inflammati¬on. J Biol Chem 2003; 278: 14677-87.
43. Simopoulos AP, Leaf A, Salem Jr N. Statement on the essentiality of and recommended dietary intakes for co-6 and co-3 fatty acids. Prostaglandins Leukot Essent Fatty Acids2000; 63: 119-21.
44.
45.
Din JN,Newby DE, Flapan AD. Omega 3 fatty acids and cardiovascular disease-fishing for a natural treatment. BMJ2004; 328; 30-5.
Goyens PL, Spilker ME, Zock PL, Katan MB, Mensink RP. Conversion of alpha-linolenic acid in humans is influenced by the absolute amounts of alpha-linolenic acid and linoleic acid in the diet and not by their ratio. Am J Clin Nutr 2006; 84: 44-53.
46. Willett WC. The role of dietary n-6 fatty acids in the prevention of car¬diovascular disease. J Cardiovasc Med 2007; 8: 42-5.
Mensink RP, Zock PL, Kester AD, Katan MB. Effects of dietary fatty acids and carbohydrates on the ratio of serum total to HDL cholesterol and on serum lipids and apolipoproteins: a meta-analysis of 60 controlled trials. Am J Clin Nutr 2003; 77: 1146-55.
Sacks FM, Campos H. Polyunsaturated fatty acids, inflammation, and cardiovascular disease: time to widen our view of the mechanisms. J Clin
Endocrinol Metab 2006; 91: 398-400.
Mozaffarian D, Ascherio A, Hu FB ve ark. Interplay between different polyunsaturated fatty acids and risk of coronary heart disease in men. Cir¬culation 2005; 111: 157-64.
Pischon T, Hankinson SE, Hotamisligil GS, Rifai N, Willett WC, Rimm
EB. Habitual dietary intake of n- 3 and n-6 fatty acids in relation to inf-lammatorymarkers among US men and women. Circulation2003; 108: 55¬160.
Hu FB, Manson JE, Stampfer MJ ve ark. Diet, lifestyle, and the risk of
type 2 diabetes mellitus in women. N Engl J Med2001; 345: 790-7.
Kris-Etherton PM, Harris WS, Appel LJ. Omega-3 fatty acids and cardi¬ovascular disease: new recommendations from the American Heart Asso¬ciation. Arterioscler Thromb Vasc Biol 2003; 23: 151-2.
Schwalfenberg G. Omega-3 fatty acids, their beneficial role in cardiovas¬cular health. Can Fam Physician 2006; 52: 734-40.
Nordoy A, Marchioli R, Arnesen H, Videbaek J. n-3 polyunsaturated fatty acids and cardiovascular diseases. Lipids2001; 36: 127-9.
Thank you for copying data from http://www.arastirmax.com
